Revance Therapeutics (RVNC) Reports Complete Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia
November 4, 2019 4:05 PM EST- DaxibotulinumtoxinA for Injection (DAXI) has potential to be first long-acting neuromodulator for treatment of this debilitating involuntary muscle movement disorder -
- Topline data expected in second half of 2020 -
NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced it has completed patient enrollment of the companys pivotal ASPEN-1 Phase 3 clinical trial for its investigational drug candidate DaxibotulinumtoxinA for Injection (DAXI) for the treatment of isolated cervical dystonia... More
